Endometrial Stromal Sarcomas: A Retrospective Analysis of 28 Patients, Single Center Experience for 20 Years
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Purpose: The aim of this study was to evaluate the behavior of endometrial stromal sarcomas (ESSs) in relation to their clinical and pathogenic features, and to determine the optimal treatment strategy. Materials and Methods: A retrospective analysis was performed involving 28 patients with histologic-proven ESSs treated at our institution between 1987 and 2006. Results: The median follow-up was 54.7±63.1 months and the 5-year survival rate was 82.0%. Twenty-two (81.5%) and 5 patients (18.5%) had low- and high-grade disease, respectively. Univariate analysis revealed that the histologic grades, based on mitotic count, were associated with longer survival (p=0.004). However, among those patients with low-grade tumors, 5/20 patients (25%) had a recurrence and 2/21 patients (9.5%) had distant metastasis during the follow-up period. With the exception of 2 patients, 26 patients with ESSs underwent hysterectomy as primary treatment. Adjuvant treatment after surgery was administered to 14/26 patients (53.8%). Hormone therapy with progesterone, chemotherapy, and/or radiotherapy did not influence overall survival. However, the postoperative adjuvant therapy group, regardless of the treatment modality, was associated with relatively increased overall survival when compared to the surgery only group (p=0.054). Conclusion: The preoperative differential diagnosis of ESSs from other benign gynecologic diseases is often difficult. We recommend adjuvant therapy be administered after hysterectomy in patients with ESS to prevent recurrence or distant metastasis. (Cancer Res Treat. 2008;40:6-10)
Abstract
Purpose: The aim of this study was to evaluate the behavior of endometrial stromal sarcomas (ESSs) in relation to their clinical and pathogenic features, and to determine the optimal treatment strategy. Materials and Methods: A retrospective analysis was performed involving 28 patients with histologic-proven ESSs treated at our institution between 1987 and 2006. Results: The median follow-up was 54.7±63.1 months and the 5-year survival rate was 82.0%. Twenty-two (81.5%) and 5 patients (18.5%) had low- and high-grade disease, respectively. Univariate analysis revealed that the histologic grades, based on mitotic count, were associated with longer survival (p=0.004). However, among those patients with low-grade tumors, 5/20 patients (25%) had a recurrence and 2/21 patients (9.5%) had distant metastasis during the follow-up period. With the exception of 2 patients, 26 patients with ESSs underwent hysterectomy as primary treatment. Adjuvant treatment after surgery was administered to 14/26 patients (53.8%). Hormone therapy with progesterone, chemotherapy, and/or radiotherapy did not influence overall survival. However, the postoperative adjuvant therapy group, regardless of the treatment modality, was associated with relatively increased overall survival when compared to the surgery only group (p=0.054). Conclusion: The preoperative differential diagnosis of ESSs from other benign gynecologic diseases is often difficult. We recommend adjuvant therapy be administered after hysterectomy in patients with ESS to prevent recurrence or distant metastasis. (Cancer Res Treat. 2008;40:6-10)
참고문헌 (25)
- Echt G., "Treatment of uterine sarcomas", Cancer, 66, pp.35~9 (1990)
- Bodner K., "Prognostic parameters in endometrial stromal sarcoma: a clinicopathologic study in 31 patients", Gynecol Oncol, 81, pp.160~5 (2001)
- Gadducci A., "Endometrial stromal sarcoma: analysis of treatment failures and survival", Gynecol Oncol, 63, pp.247~53 (1996)
- Norris HJ, "Mesenchymal tumors of the uterus. I. A clinical and pathological study of 53 endometrial stromal tumors", Cancer, 19, pp.755~66 (1966)
- Amant F., "The classification of a uterine sarcoma as ‘high-grade endometrial stromal sarcoma' should be abandoned", Gynecol Oncol, 95, pp.412~3 (2004)
- Chang KL, "Primary uterine endometrial stromal neoplasms. A clinicopathologic study of 117 cases", Am J Surg Pathol, 14, pp.415~38 (1990)
- Li AJ, "Ovarian preservation in stage I low-grade endometrial stromal sarcomas", Obstet Gynecol, 106, pp.1304~8 (2005)
- Berchuck A., "Treatment of endometrial stromal tumors", Gynecol Oncol, 36, pp.60~5 (1990)
- Mansi JL, "Endometrial stromal sarcomas", Gynecol Oncol, 36, pp.113~8 (1990)
- Creasman WT, "Surgical pathologic spread patterns of endometrial cancer. A Gynecologic Oncology Group Study", Cancer, 60, pp.2035~41 (1987)
- Bohr L., "Low-grade stromal sarcoma: a benign appearing malignant uterine tumour; a review of current literature. Differential diagnostic problems illustrated by four cases", Eur J Obstet Gynecol Reprod Biol, 39, pp.63~9 (1991)
- Cacciatore B., "Ultrasound findings in uterine mixed mullerian sarcomas and endometrial stromal sarcomas", Gynecol Oncol, 35, pp.290~3 (1989)
- Ueda M., "MR imaging findings of uterine endometrial stromal sarcoma: differentiation from endometrial carcinoma", Eur Radiol, 11, pp.28~33 (2001)
- Leath CA 3rd, "A multi-institutional review of outcomes of endometrial stromal sarcoma", Gynecol Oncol, 105, pp.630~4 (2007)
- Lin YC, "Prolonged stabilization of progressive endometrial stromal sarcoma with prolonged oral etoposide therapy", Gynecol Oncol, 58, pp.262~5 (1995)
- Riopel J., "Lymph node metastases in low-grade endometrial stromal sarcoma", Gynecol Oncol, 96, pp.402~6 (2005)
- Haberal A., "Endometrial stromal sarcoma of the uterus: analysis of 25 patients", Eur J Obstet Gynecol Reprod Biol, 109, pp.209~13 (2003)
- Sutton G., "Ifosfamide treatment of recurrent or metastatic endometrial stromal sarcomas previously unexposed to chemotherapy: a study of the Gynecologic Oncology Group", Obstet Gynecol, 87, pp.747~50 (1996)
- Muss HB, "Treatment of recurrent or advanced uterine sarcoma. A randomized trial of doxorubicin versus doxorubicin and cyclophosphamide (a phase III trial of the Gynecologic Oncology Group)", Cancer, 55, pp.1648~53 (1985)
- Szlosarek PW, "Effective treatment of a patient with a high-grade endometrial stromal sarcoma with an accelerated regimen of carboplatin and paclitaxel", Anticancer Drugs, 11, pp.275~8 (2000)
- Yamawaki T., "Treatment of stage IV “high-grade” endometrial stromal sarcoma with ifosfamide, adriamycin, and cisplatin", Gynecol Oncol, 64, pp.265~9 (1997)
- Chu MC, "Schwartz PE. Low-grade endometrial stromal sarcoma: hormonal aspects", Gynecol Oncol, 90, pp.170~6 (2003)
- Pink D., "Harm or benefit of hormonal treatment in metastatic low-grade endometrial stromal sarcoma: single center experience with 10 cases and review of the literature", Gynecol Oncol, 101, pp.464~9 (2006)
- Amant F., "Clinical study investigating the role of lymphadenectomy, surgical castration and adjuvant hormonal treatment in endometrial stromal sarcoma", Br J Cancer, 97, pp.1194~9 (2007)
- Weitmann HD, "Radiation therapy in the treatment of endometrial stromal sarcoma", Int J Radiat Oncol Biol Phys, 49, pp.739~48 (2001)